Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate

Author: Benzinga Newsdesk | November 05, 2025 08:34am
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(3.27) by 75.84 percent. This is a 85.15 percent increase over losses of $(5.32) per share from the same period last year.

Posted In: TPST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist